Tadalafil Tablet, Film Coated
Product Images NDC 72789-407

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 72789-407). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72789407 Label (72789407)

Label for Tadalafil USP 5 mg film-coated tablets by PD-Rx Pharmaceuticals, Inc. The package contains 30 tablets. The label includes dosage strength (5 mg), NDC 72789-407-30, expiration date 12/2025, lot number H24B18, and a warning to keep out of reach of children. Manufacturer location is Oklahoma City, OK.*

FDA Label Image

Tadalafil-figure-1 (Tadalafil Figure 1)

A set of four line graphs showing changes in blood pressure over time comparing Tadalafil versus placebo. The graphs depict standing systolic BP, standing diastolic BP, supine systolic BP, and supine diastolic BP, with differences measured in mmHg on the y-axis and time in hours on the x-axis, including error bars for variability.*

FDA Label Image

Tadalafil-figure-2 (Tadalafil Figure 2)

Two line graphs showing the change in standing and supine systolic blood pressure (mmHg) over 24 hours post-dose. The top graph compares Tadalafil 20 mg with doxazosin 8 mg (solid line) and placebo with doxazosin 8 mg (dotted line). The bottom graph shows similar comparisons for supine systolic blood pressure versus time after dosing.*

FDA Label Image

Tadalafil-figure-3 (Tadalafil Figure 3)

Line graph illustrating systolic blood pressure (mmHg) changes over 12 hours after administration of 20 mg tadalafil or placebo combined with 8 mg doxazosin at different dosing times (08:00 and 20:00). The graph compares four conditions showing blood pressure trends relative to time after dosing.*

FDA Label Image

Tadalafil-figure-4 (Tadalafil Figure 4)

A line graph depicting plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose after 5 consecutive days. The y-axis shows concentration up to 500 µg/L, and the x-axis spans 0 to 120 hours. Data points include error bars indicating variability.*

FDA Label Image

Tadalafil-figure-5 (Tadalafil Figure 5)

A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment between Tadalafil 5 mg tablets and placebo. The x-axis represents duration of treatment in weeks (0, 4, 8, and 12), and the y-axis shows the change from baseline in IPSS total score, with greater negative values indicating improvement. The Tadalafil 5 mg line shows a steeper and more sustained decrease in IPSS score compared to placebo, with statistical significance indicated at certain points (P < 0.01).*

FDA Label Image

Tadalafil-figure-6 (Tadalafil Figure 6)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks of treatment with Tadalafil 5 mg tablets versus placebo. The x-axis represents treatment duration in weeks, and the y-axis shows the change in score. The graph indicates a greater decrease in score with Tadalafil versus placebo, with statistically significant differences marked (P < 0.01).*

FDA Label Image

Tadalafil-figure-7 (Tadalafil Figure 7)

A line graph showing the least-squares mean change from baseline over 26 weeks of therapy. The graph compares two groups: Tadalafil/Finasteride and Placebo/Finasteride. Data points are shown at weeks 0, 4, 12, and 26 with Tadalafil/Finasteride consistently showing greater reduction. Statistical significance (p<0.001 and p<0.05) is marked at weeks 4, 12, and 26.*

FDA Label Image

Tadalafil-figure-8 (Tadalafil Figure 8)

A line graph showing the change from baseline in IPSS Total Score over a 12-week treatment duration comparing Tadalafil 5 mg tablets and placebo. The x-axis represents weeks of treatment, and the y-axis shows the change from baseline score, with Tadalafil showing a greater reduction than placebo, statistically significant at 12 weeks (p<0.01).*

FDA Label Image

Tadalafil-structure (Tadalafil Structure)

Chemical structure diagram of Tadalafil, a prescription drug. The diagram shows the molecular framework including fused rings and functional groups characteristic of Tadalafil's chemical composition.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.